KAI407, a Potent Non-8-Aminoquinoline Compound That Kills Plasmodium cynomolgi Early Dormant Liver Stage ParasitesIn Vitro
Authors:
Open Access
- 1 March 2014
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (3) , 1586-1595
Abstract
Preventing relapses ofPlasmodium vivaxmalaria through a radical cure depends on use of the 8-aminoquinoline primaquine, which is associated with safety and compliance issues. For future malaria eradication strategies, new, safer radical curative compounds that efficiently kill dormant liver stages (hypnozoites) will be essential. A new compound with potential radical cure activity was identified using a low-throughput assay ofin vitro-cultured hypnozoite forms ofPlasmodium cynomolgi(an excellent and accessible model forPlasmodium vivax). In this assay, primary rhesus hepatocytes are infected withP. cynomolgisporozoites, and exoerythrocytic development is monitored in the presence of compounds. Liver stage cultures are fixed after 6 days and stained with anti-Hsp70 antibodies, and the relative proportions of small (hypnozoite) and large (schizont) forms relative to the untreated controls are determined. This assay was used to screen a series of 18 known antimalarials and 14 new non-8-aminoquinolines (preselected for blood and/or liver stage activity) in three-point 10-fold dilutions (0.1, 1, and 10 μM final concentrations). A novel compound, designated KAI407 showed an activity profile similar to that of primaquine (PQ), efficiently killing the earliest stages of the parasites that become either primary hepatic schizonts or hypnozoites (50% inhibitory concentration [IC50] for hypnozoites, KAI407, 0.69 μM, and PQ, 0.84 μM; for developing liver stages, KAI407, 0.64 μM, and PQ, 0.37 μM). When given as causal prophylaxis, a single oral dose of 100 mg/kg of body weight prevented blood stage parasitemia in mice. From these results, we conclude that KAI407 may represent a new compound class forP. vivaxmalaria prophylaxis and potentially a radical cure.Keywords
This publication has 54 references indexed in Scilit:
- Imidazolopiperazines: Lead Optimization of the Second-Generation Antimalarial AgentsJournal of Medicinal Chemistry, 2012
- Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug DiscoveryScience, 2011
- Spiroindolones, a Potent Compound Class for the Treatment of MalariaScience, 2010
- Plasmodium falciparum PF10_0164 (ETRAMP10.3) Is an Essential Parasitophorous Vacuole and Exported Protein in Blood StagesEukaryotic Cell, 2010
- Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy peopleProceedings of the National Academy of Sciences, 2010
- Randomized, Double-Blind Study of the Safety, Tolerability, and Efficacy of Tafenoquine versus Mefloquine for Malaria Prophylaxis in Nonimmune SubjectsAntimicrobial Agents and Chemotherapy, 2010
- Resistance to Therapies for Infection byPlasmodium vivaxClinical Microbiology Reviews, 2009
- Statistical Model To Evaluate In Vivo Activities of Antimalarial Drugs in a Plasmodium cynomolgi -Macaque Model for Plasmodium vivax MalariaAntimicrobial Agents and Chemotherapy, 2009
- In silicoactivity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screenProceedings of the National Academy of Sciences of the United States of America, 2008
- Antiparasitic Activities and Toxicities of Individual Enantiomers of the 8-Aminoquinoline 8-[(4-Amino-1-Methylbutyl)Amino]-6-Methoxy-4-Methyl-5-[3,4-Dichlorophenoxy]Quinoline SuccinateAntimicrobial Agents and Chemotherapy, 2008